Table 3

Biomarker levels in each subgroups according to the presence or absence of knee pain

Pain

Mean

SE

95% CI of the mean

P-value

95% CI for difference

Lower

Upper


sC2C

-

5.47

0.04

5.40

5.55

0.01*

-0.35 to -0.05

Ln (pmol/ml)

+

5.67

0.06

5.55

5.79

sCPII

-

7.28

0.07

7.14

7.43

0.03*

-0.62 to -0.04

Ln (ng/ml)

+

7.62

0.12

7.37

7.86

uCTX-II/Cr

-

5.14

0.12

4.90

5.38

<0.01*

-1.30 to -0.34

Ln (ng/╬╝mol creatinine)

+

5.96

0.20

5.56

6.37

sC2C/sCPII

-

0.19

0.02

0.14

0.23

0.40

-0.05 to 0.13

+

0.15

0.04

0.07

0.22

uCTX-II/sCPII

-

0.19

0.07

0.06

0.32

0.25

-0.42 to 0.12

+

0.34

0.11

0.12

0.57

uNTx/Cr

-

3.60

0.09

3.41

6.79

0.05*

-0.76 to 0.03

Ln (ng/ml creatinine)

+

3.98

016

3.66

4.30

sHA

-

3.03

0.12

2.78

3.28

0.04*

-1.03 to -0.03

Ln (pmol/ml)

+

3.55

0.21

3.13

3.98


All analyses were adjusted for age, gender, and body mass index. The urinary biomarkers were corrected for creatinine. The number of subjects with knee pain was 30, while the number without knee pain was 16. *P-values less than or equal to 0.05 are statistically significant.

95% CI, 95% confidence interval; C2C, cartilage collagen type II cleavage; CPII, cartilage type II collagen carboxy propeptide; CTX-II, type II collagen C-telopeptide; HA, hyaluronic acid; K/L, Kellgren-Lawrence grade; Ln, natural log; NTx, N-terminal crosslinking telopeptide of type I collagen; s, serum; SE, standard error of the mean; u, urine.

Ishijima et al. Arthritis Research & Therapy 2011 13:R22   doi:10.1186/ar3246

Open Data